In summary, these results may shed light on the different mechanisms of resistance to anti-EGFR treatment in solid tumors experiencing high cell-cell contact vs. metastatic and circulating tumor cells experiencing minimal cell-cell contact. This evidence concerns the gene EGFR and neoplasm.